



Tidsskriftet
DEN NORSKE LEGEFORENING

Laparoscopic gastric bypass versus lifestyle intervention for adolescents with morbid obesity

ORIGINALARTIKKEL

JØRAN HJELMESÆTH

E-mail: joran.hjelmeseth@siv.no

Morbid Obesity Center, South-Eastern Norway Regional Health Authority
Vestfold Hospital Trust
and

Department of Endocrinology, Morbid Obesity and Preventive Medicine
University of Oslo

He prepared the first draft of the manuscript and contributed to the study concept and design, data analysis and interpretation, literature search, revision of the manuscript, and approved the final version.

Professor Jøran Hjelmesæth, MD PhD, is Director of the Morbid Obesity Center, South-Eastern Norway Regional Health Authority. He heads the Norwegian Nutrition Council and is the 4XL study chair. The author has completed the ICMJE form and declares no conflicts of interest.

JENS KRISTOFFER HERTEL

Morbid Obesity Center, South-Eastern Norway Regional Health Authority
Vestfold Hospital Trust

He is a member of the study board and contributed to the study design, data analysis and interpretation, drafting/revision of the manuscript and figures, and approved the submitted version.

Jens Kristoffer Hertel, PhD, senior researcher and head of the research department. The author has completed the ICMJE form and declares no conflicts of interest.

ANE HJETLAND HOLT

Morbid Obesity Center, South-Eastern Norway Regional Health Authority
Vestfold Hospital Trust

She contributed to data collection and interpretation and to revision of the manuscript, and approved the submitted version.

Ane Hjetland Holt is a medical doctor.

The author has completed the ICMJE form and declares no conflicts of interest.

BEATE BENESTAD

Morbid Obesity Center, South-Eastern Norway Regional Health Authority
Vestfold Hospital Trust

She contributed to data collection and interpretation, literature search, revision of the manuscript, and approved the submitted version.

Beate Benestad is a medical doctor and doctoral research fellow.

The author has completed the ICMJE form and declares no conflicts of interest.

LARS THOMAS SEEBERG

Department of Surgical Oncology
Vestfold Hospital Trust

He has performed bariatric surgery, and contributed to data collection and interpretation and to revision of the manuscript, and approved the submitted version.

Lars Thomas Seeberg, MD PhD, gastrosurgeon with expertise in bariatric surgery.
The author has completed the ICMJE form and declares no conflicts of interest.

MORTEN LINDBERG

Department of Laboratory Medicine
Vestfold Hospital Trust

He contributed to data collection, analysis and interpretation, literature search and to revision of the manuscript, and approved the submitted version.

Morten Lindberg, MD PhD, is a senior consultant.

The author has completed the ICMJE form and declares no conflicts of interest.

ERLING HALVORSEN

Department of Radiology
Vestfold Hospital Trust

He contributed to data collection, analysis and interpretation, to revision of the manuscript, and approved the submitted version.

Erling Halvorsen is a senior bioengineer.

The author has completed the ICMJE form and declares no conflicts of interest.

PÉTUR BENEDIKT JÚLÍUSSON

Health Registries Research and Development
Norwegian Institute of Public Health, Bergen
and

Department of Paediatric and Adolescent Medicine
Haukeland University Hospital
and

Department of Clinical Science
University of Bergen

He is a member of the study board, contributed to data analysis and interpretation and to revision of the manuscript, and approved the submitted version.

Professor Pétur Benedikt Júlíusson, MD PhD, is a senior consultant and departmental director, with expertise in paediatric endocrinology and obesity in children and adolescents.

The author has completed the ICMJE form and declares no conflicts of interest.

RUNE SANDBU

Morbid Obesity Center, South-Eastern Norway Regional Health Authority
Vestfold Hospital Trust
and

Department of Surgical Oncology
Vestfold Hospital Trust

He has performed bariatric surgery, and contributed to the study concept and design, data interpretation and revision of the manuscript, and approved the submitted version.

Rune Sandbu, MD PhD, is a senior researcher and head of department, and is in charge of the surgery component of the 4XL study.

The author has completed the ICMJE form and declares no conflicts of interest.

SAMIRA LEKHAL

Morbid Obesity Center, South-Eastern Norway Regional Health Authority
Vestfold Hospital Trust

She contributed to the study concept and design, data collection and interpretation, literature search, and to revision of the manuscript, and approved the submitted version.

Samira Lekhal, MD PhD, is a senior researcher and senior consultant/head of section. She is the principal investigator for the 4XL study.

The author has completed the ICMJE form and declares no conflicts of interest.

BACKGROUND

There is limited evidence for the effectiveness of bariatric surgery in adolescents, and the associated complications. The main objective of the 4XL study was to clarify whether laparoscopic Roux-en-Y gastric bypass (LGBP) combined with lifestyle intervention is a safe and effective treatment method.

MATERIAL AND METHOD

Data were retrieved from an ongoing non-randomised intervention study of adolescents with morbid obesity that is comparing the effects of gastric bypass combined with lifestyle intervention versus lifestyle intervention alone.

RESULTS

Altogether 39 patients (64 % girls) treated with a gastric bypass, and 96 patients (57 % girls) treated with lifestyle intervention were examined prior to the start of treatment and one year later. The average age at inclusion (SD) was 16.7 (1.0) years vs. 15.6 (1.3) years, and average BMI was 45.6 (4.4) vs. 43.3 (4.1) kg/m² in the two groups. Average (95 % CI) percentage weight loss was 30 % (27 %–33 %) after surgery versus weight gain of 1 % (–1 % to 3 %) in the control group. The difference between the groups was 31 % (95 % CI 27 %–34 %, $p < 0.001$).

Cardiometabolic risk factors improved only after surgery. After gastric bypass, two early (<6 weeks) minor complications were recorded. One year after surgery, 4 (10 %), 8 (21 %) and 4 (10 %) of patients had anaemia, iron deficiency or low vitamin B₁₂ levels respectively, and 20 of 33 patients (61 %) had low two-hour blood glucose (<2.8 mmol/l) after oral glucose tolerance testing.

INTERPRETATION

The results support previous studies showing that gastric bypass is associated with significant weight loss in adolescent patients with morbid obesity. The 4XL study is currently too small and the follow-up time too short to allow the risk of long-term complications to be assessed.

Morbid obesity in adolescents is associated with an increased risk of comorbidities, including non-alcoholic fatty liver disease, type 2 diabetes, cardiovascular disease, mental illness, and morbid obesity in adulthood, as well as reduced life expectancy (1, 2). Effective treatment can therefore provide substantial benefits, both for the individual and for society (3).

Conservative treatment of morbid obesity in adolescents uses an interdisciplinary approach and family-based behavioural therapy to support changes in lifestyle habits related to diet and physical activity. This approach results on average in low to moderate levels of weight loss (4, 5).

In adults, bariatric (weight-loss) surgery has been shown to produce good results, with lasting weight loss and improvement in comorbidities, but also an increased risk of complications in the short and long term (6, 7). Prior to the start of the 4XL study in 2009, little was known about the effectiveness of bariatric surgery in adolescents and the associated complications (8). Eleven years later, the evidence base remains uncertain (3, 9).

The primary research question in the 4XL study was to clarify whether laparoscopic Roux-en-Y gastric bypass surgery (hereafter referred to as a gastric bypass) combined with lifestyle intervention is an effective and safe weight-loss treatment. This article compares the results of bariatric surgery and non-surgical treatment after one year.

Material and method

The 4XL study is an ongoing prospective clinical intervention study in patients aged 13–18 years who seek treatment at the Morbid Obesity Center, South-Eastern Norway Regional Health Authority, Vestfold Hospital Trust – a regional centre of excellence for the holistic and interdisciplinary treatment of morbid obesity in children, adolescents and adults. The study began in 2009, and the current analysis uses data from patients recruited in the period 8 October 2009–19 April 2018.

Children, adolescents and families with morbid obesity can be referred from either the primary or secondary healthcare services for treatment at the centre. At the first consultation, all families are informed about and invited to participate in the Vestfold Child Obesity Register ('*Barnefedmeregisteret i Vestfold*'), an opt-in prospective register, where personal information and biological material are collected for storage in a research biobank (4). Treatment is provided by an interdisciplinary team including a doctor, clinical nutritionist, nurse, specialist physiotherapist and health educator (appendix). The primary aim of the 4XL study is to clarify whether gastric bypass combined with lifestyle intervention provides greater health benefits than lifestyle intervention alone in the short and long term (1–10 years) and to survey complications after surgery.

As both the recruitment of suitable patients to the study and the dropout rate have been lower than expected, the study board has decided to analyse and publish the existing one-year data.

PARTICIPANTS

Patients who wish to undergo surgical treatment and who have completed at least one year of conservative interdisciplinary treatment in the Norwegian healthcare service without a satisfactory outcome can be referred for eligibility assessment for the 4XL study. Eligible patients undergo a standard length gastric bypass on a Roux limb (120 cm) in addition to standard lifestyle intervention (4). All anastomoses are performed using staples.

Inclusion criteria are age 13–18 years, BMI ≥ 40 kg/m², or BMI ≥ 35 kg/m² with at least one comorbidity, and Tanner stage 4–5 of pubertal development.

Exclusion criteria are BMI ≥ 55 kg/m², significant risk of non-compliance, certain obesity syndromes, obesity caused by brain damage, and serious general illness.

The control group (those who receive lifestyle intervention) consists of patients who have not expressed a desire for surgery, but who have agreed to be included in the Vestfold Child Obesity Register, and who are undergoing conservative treatment at the centre over the same period. They must also meet the inclusion criteria for surgery (age, BMI). Some of the results following conservative treatment have been published previously (4).

OUTCOMES

The primary outcomes in this analysis are BMI and percentage weight loss one year after surgery/treatment start. Secondary outcomes are cardiometabolic risk factors (dyslipidaemia, inflammation, hypertension, dysglycaemia, fatty liver disease), early postoperative complications (graded from mild (grade I) to death (grade IV) within six weeks of surgery according to the Contracted Accordion Classification system), bone mineral density, anaemia, as well as various vitamin and mineral deficiencies (thiamine, vitamin B₁₂, vitamin D, iron, calcium), and two-hour blood glucose after an oral glucose tolerance test. The primary outcomes were supplemented with measurement of waist circumference and body composition (fat percentage, fat mass, fat-free mass).

MEASUREMENTS

Height is measured using a stadiometer (Seca 264, Seca, Hamburg, Germany), and weight and body composition are measured using bioelectrical impedance analysis (BC-418 Segmental Body Composition Analyzer, Tanita Corporation, Tokyo, Japan). Waist

circumference is measured horizontally midway between the lowest rib and the iliac crest. Blood pressure is measured using Dinamap ProCare (GE Healthcare, Buckinghamshire, UK), and the average of three measurements is calculated. Smoking is self-reported (yes/no) upon inclusion.

Routine medical biochemical analyses are performed at the Department of Laboratory Medicine, Vestfold Hospital Trust. The laboratory is accredited according to the standard NS-EN ISO 15189. LDL cholesterol ≥ 2.8 mmol/L and non-HDL cholesterol ≥ 3.1 mmol/L were considered elevated, with an increased risk of cardiovascular disease (10). Normal glucose tolerance, prediabetes and type 2 diabetes are defined as HbA_{1c} $< 5.7\%$, $5.7\text{--}6.4\%$ and $\geq 6.5\%$, respectively (11). Hypertension is defined as systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 80 mm Hg (12). Bone mineral density (BMD z-score) and whole body bone mineral content (BMC) are measured via dual X-ray absorptiometry (DXA) with a Hologic Delphi W instrument (Hologic, Marlborough, MA, USA). Serum alanine aminotransferase values (s-ALT) above 34 U/L in boys and 24 U/L in girls were used as a surrogate marker for fatty liver disease (13).

SAMPLE SIZE

Based on our clinical experience, we expected an average weight loss of 25% (10 BMI units) in the surgery group and up to 10% (4 BMI units) in the lifestyle group (standard deviation (SD) 5). A total of 42 patients would need to complete the study (21 with surgery and 21 with conservative treatment) to provide more than 90% power to detect such a difference (6 BMI units) with a significance level (alpha) of 0.01. The dropout rate was expected to be up to 30%. We planned to include 50 patients in the surgery group to enable the incidence of serious postoperative complications to be assessed in addition.

STATISTICAL METHODS

Treatment groups were compared prior to the start of treatment using t-tests, Mann-Whitney tests or Fisher's exact test. Changes from pre-treatment baseline to the one-year follow-up were analysed with paired t-tests or McNemar's test. The groups were compared after one year using analysis of covariance (ANCOVA), with adjustment for the baseline value of the dependent variable, unpaired t-tests, or logistic regression with the baseline value of the dependent variable as a covariate. P-values < 0.05 were considered statistically significant.

ETHICS

The 4XL study has been approved by the Regional Committee for Medical and Health Research Ethics (REC) South-East (reference S-08584c 2008/14165) and recommended by the Data Protection Officer for Research and the Norwegian Centre for Research Data (project no. 21242). The Vestfold Child Obesity Register has been approved by the Regional Committee for Medical and Health Research Ethics (S-08742c 2008/19081), the Norwegian Centre for Research Data, has a concession from the Norwegian Data Protection Authority (20789 grh/rh) and has been recommended by a local Data Protection Officer. The Register's research biobank has been approved by the Norwegian Directorate of Health. The study was registered at ClinicalTrials.gov on 18 June 2009 (NCT00923819).

Results

A total of 510 adolescent patients began treatment at the Morbid Obesity Center, South-Eastern Norway Regional Health Authority, Vestfold Hospital Trust in the period 8 October 2009–19 April 2018 (Figure 1). Nineteen of 60 patients referred for surgery did not meet the inclusion criteria. The other 41 were eligible and underwent surgery, and 39 of these attended a one-year follow-up. A total of 139 patients began treatment in the lifestyle intervention group, of whom 96 attended a one-year follow-up. The patients in the lifestyle group who attended the one-year follow-up ($n = 96$) were slightly younger than those who

did not attend (n = 43). There was also a tendency for those who did not attend to have higher bodyweight and a larger waist circumference (Table 1).




Figure 1 Distribution of patients aged 13–18 years with BMI 35 kg/m² or above in the lifestyle intervention (n = 139) or surgical (n = 41) treatment groups among 510 adolescent patients who began treatment at the Morbid Obesity Center in the period 8 October 2009–19 April 2018.

Table 1

Baseline characteristics of adolescents aged 13–18 years with morbid obesity who began lifestyle intervention treatment at the Morbid Obesity Center in Vestfold in the period 8 October 2009–19 April 2018. Data are presented separately for patients who attended and did not attend one-year follow-up. Values are presented as mean (SD) unless otherwise stated.

	Lifestyle intervention group who attended one-year follow-up (n = 96)	Lifestyle intervention group who did not attend one-year follow-up (n = 43)
Sex		
Girls, number (%)	55 (57)	22 (51)
Boys, number (%)	41 (43)	21 (49)
Age (years)	15.6 (1.3)	16.1 (1.4)
Anthropometry and body composition		
Weight (kg)	124 (20)	130 (17)
Height (cm)	169 (9)	172 (10)
Body mass index (kg/m ²)	43.3 (4.1)	44.0 (3.1)
Waist circumference (cm)	120 (13)	124 (10)
Fat percentage	49 (6)	49 (5)
Fat mass (kg)	61 (14)	64 (11)

Before the start of treatment, patients in the surgery group (n = 39) were on average one year older and 2 BMI points heavier than those in the lifestyle group (n = 96) (Table 2). Gender distribution, mean waist circumference, fat mass, fat percentage and the percentage of patients with various cardiometabolic risk factors did not differ significantly between the groups (Table 2).

Table 2

Baseline characteristics of adolescents aged 13–18 years with morbid obesity who began treatment at the Morbid Obesity Center in Vestfold in the period 8 October 2009–19 April 2018 and who attended one-year follow-up. Values are presented as number (%) unless otherwise stated.

	Surgery + lifestyle intervention (n = 39)	Lifestyle intervention (n = 96)	P-value ¹
Sex			
Girls	25 (64)	55 (57)	0.56
Boys	14 (36)	41 (43)	
Age (years)			
Median (from lowest to highest value)	16.9 (14.2–18.0)	15.6 (13.0–18.0)	< 0.001
Anthropometry and body composition, mean (SD)			
Body weight (kg)	132 (14)	124 (20) ²	0.024
Height (cm)	170 (8)	169 (9) ²	0.42
BMI (kg/m ²)	45.6 (4.4)	43.3 (4.1) ²	0.004
Waist circumference (cm)	124 (11)	120 (13) ³	0.098
Fat percentage	50 (6) ⁴	49 (6) ⁵	0.53
Fat mass (kg)	66 (11) ⁴	61 (14) ⁵	0.075
Fat-free mass (kg)	66 (10) ⁴	63 (12) ⁵	0.13
Cardiometabolic risk factors			
Hypertension	8 (21)	19 (20)	1.00
Hypercholesterolaemia (non-HDL)	22 (56)	65 (68)	0.24
C-reactive protein ≥ 3 mg/L	31 (80)	66 (70) ²	0.39
Smoker	8 (21)	10 (10) ³	0.18
Type 2 diabetes	3/38 (8)	1 (1)	0.12
Prediabetes	6/38 (16)	14 (15) ²	
Normal glucose tolerance	29/38 (76)	79 (84) ²	
Fatty liver disease			
ALT > 24 U/L girls/> 34 U/L boys	17/39 (44)	43/95 (45)	1.00

¹t-test, Mann-Whitney test or Fisher's exact test.

²n = 94

³n = 92

⁴n = 37

⁵n = 93

PRIMARY OUTCOMES

BMI decreased by an average of 14.1 (95 % CI 12.7 to 15.6) points in the surgery group and by 0.4 (−0.3 to 1.2) points in the lifestyle group. The estimated between-group difference after one year was 13.2 (11.7 to 14.7) BMI points. A total of 23 (25 %) and 13 (14 %) patients in the lifestyle group had a BMI reduction of at least 5 % and 10 % respectively, compared with 100 % and 97 % in the surgery group (Figure 2). Mean percentage weight loss was 30 % (27 to 33 %) in the surgery group compared with a weight gain of 1 % (−1 to 3 %) in the lifestyle group; observed difference 31 % (27 to 34 %), p < 0.001 (Table 3).




Figure 2 Individual variation in percentage change in BMI one year after the start of treatment in the two groups. Each bar represents the change in a single patient. Partial overlap with data from (4) for the lifestyle group.

Table 3

Observed primary (BMI and percentage weight change) and secondary outcome measures at one-year follow-up and baseline-adjusted estimated differences or observed percentage differences between the groups. Included are adolescents with morbid obesity who began treatment at the Morbid Obesity Center in Vestfold in the period 8 October 2009–19 April 2018 and who attended one-year follow-up. Values are presented as mean (SD) unless otherwise stated.

	Surgery + lifestyle intervention (n = 39) ¹	Lifestyle intervention (n = 96) ¹	Between-group difference or odds ratio (95 % CI)	P-value ²
Primary endpoints and body composition				
BMI (kg/m ²)	31.5 (4.4)	42.7 (5.2)	13.2 (11.7 to 14.7)	< 0.001
BMI change (95 % CI)	-14.1 (-15.6 to -12.7)	-0.4 (-1.2 to 0.3)	Not calculated	
Percentage weight change (95 % CI)	-30 (-33 to -27)	1 (-1 to 3)	31 (27 to 34)	< 0.001
Waist circumference (cm)	95 (12)	118 (13)	26 (22 to 29)	< 0.001
Fat mass (kg)	31.6 (9.7)	58.2 (14.2)	31.3 (27.2 to 35.5)	< 0.001
Fat-free mass (kg)	60.7 (11.2)	63.4 (11.5)	6.0 (3.5 to 8.5)	< 0.001
Fat percentage	35 (10)	47 (7)	14 (12 to 17)	< 0.001
Secondary endpoints				
Dyslipidaemia				
Total cholesterol (mmol/L)	3.6 (0.7)	4.4 (0.8)	0.84 (0.63 to 1.05)	< 0.001
LDL cholesterol (mmol/L)	2.0 (0.7)	2.7 (0.8)	0.82 (0.61 to 1.03)	< 0.001
HDL cholesterol (mmol/L)	1.3 (0.3)	1.2 (0.2)	-0.23 (-0.30 to -0.16)	< 0.001
Triglycerides (mmol/L)	0.9 (0.3)	1.5 (0.8)	0.61 (0.35 to 0.86)	< 0.001

	Surgery + lifestyle intervention (n = 39) ¹	Lifestyle intervention (n = 96) ¹	Between-group difference or odds ratio (95 % CI)	P-value ²
Primary endpoints and body composition				
Non-HDL cholesterol ≥ 3.1 mmol/L	5/38 (13 %)	56/88 (64 %)	0.06 (0.02 to 0.19)	< 0.001
LDL cholesterol ≥ 2.8 mmol/L	4/38 (11 %)	41/87 (47 %)	0.08 (0.02 to 0.30)	< 0.001
Inflammation				
C-reactive protein (mg/L) (median/25–75 %)	0.4 (0.1–0.8)	4.0 (1.6–8.0)	3.7 (1.9 to 5.5)	< 0.001
C-reactive protein ≥ 3 mg/L	2/39 (5 %)	56/91 (62 %)	0.016 (0.003 to 0.077)	< 0.001
Hypertension				
Systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 80 mm Hg	2/39 (5 %)	13/89 (15 %)	0.29 (0.06 to 1.41)	0.13
Dysglycaemia and insulin				
Type 2 diabetes or prediabetes	0/37 (0 %)	13/86 (15 %)	NA	0.010
HbA1c (%)	5.3 (1.0)	5.4 (0.5)	0.11 (0.02 to 0.19)	0.019
Fasting blood glucose (mmol/L)	4.6 (0.8)	4.9 (1.1)	0.41 (0.20 to 0.63)	< 0.001
Insulin (pmol/L)	58 (22)	200 (172)	129 (73 to 185)	< 0.001
Homeostatic model assessment of insulin resistance	2.0 (0.8)	7.7 (9.0)	5.0 (2.5 to 7.4)	< 0.001
Fatty liver disease				
ALT (U/L)	23 (11)	35 (31)	9 (1 to 16)	0.025
ALT > 24 U/L girls/> 34 U/L boys	8/38 (21 %)	43/88 (49 %)	0.20 (0.07 to 0.56)	0.005

¹The majority of one-year values are based on data from at least 37 of 39 (95 %) patients in the surgery group (with the exception of insulin level and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), 36/39), and at least 88 of 96 (92 %) patients in the control group (with the exception of waist circumference, 81/96, insulin level and HOMA-IR, 85/96).

²Changes from pre-treatment baseline to one-year follow-up were analysed with paired t-tests. Between-group comparisons after one year were performed using analysis of covariance (ANCOVA) adjusting for baseline values of the dependent variable, unpaired t-tests, quantile regression or logistic regression with the baseline value of the dependent variable as a covariate.

SECONDARY OUTCOMES

The percentage of patients with hypercholesterolaemia or elevated C-reactive protein (≥ 3 mg/L) fell significantly more in the surgery group than in the lifestyle group, all odds ratios (OR) < 0.09 (Table 3). All patients with dysglycaemia (type 2 diabetes or prediabetes) were normoglycaemic one year after surgery, and no normoglycaemic patients developed dysglycaemia after surgery. A total of 8 of 14 (57 %) patients with prediabetes in the lifestyle group became normoglycaemic, whereas 6 of 71 (9 %) normoglycaemic patients developed prediabetes.

COMPLICATIONS AND ADVERSE EFFECTS

Two early (<6 weeks) minor surgical complications were registered. There were no statistically significant reductions in mean haemoglobin, albumin or vitamins and minerals at the one-year follow-up, but 4 (10 %) patients had anaemia, 8 (21 %) had iron deficiency and 4 (10 %) had low vitamin B₁₂. A total of 20 of 33 (61 %) patients had low two-hour blood glucose (< 2.8 mmol/L) after an oral glucose tolerance test (Table 4). Bone mineral content (BMC) and bone mineral density (BMD z-score) both decreased significantly, by an average of 3.5 % (BMC) and 0.5 standard deviations (BMD z-score), both p-values < 0.001 (Table 4). One patient had a BMD z-score < -2.0 (-2.1) after one year.

Table 4

Vitamins, minerals, albumin, haemoglobin, bone health and hypoglycaemia after 75 g glucose in an oral glucose tolerance test, prior to the start of treatment and after one year in adolescents with morbid obesity who underwent a gastric bypass in combination with lifestyle intervention at the Morbid Obesity Center in Vestfold in the period 8 October 2009–19 April 2018 and who attended one-year follow-up. Mean (SD) or number (%).

Outcome measure	Baseline	One-year ¹	Change (95 % CI)	P-value ²
Haemoglobin and anaemia				
Haemoglobin (g/dL)	13.7 (1.1)	13.5 (1.5)	-0.19 (-0.50 to 0.11)	0.21
Hb <12 g/dL girls/<13 g/dL boys	1/39 (2.6 %)	4/39 (10 %)		0.63
Albumin (g/L)	41.9 (3.0)	40.9 (3.6)	-1.0 (-2.02 to 0.07)	0.067
Iron and iron deficiency				
Ferritin (µg/L)	50 (30)	47 (42)	-3 (-16 to 10)	0.65
Ferritin <15 µg/L	0/39 (0 %)	8/39 (21 %)		NA
Vitamins, PTH and calcium				
Thiamine (nmol/L)	165 (32)	158 (33)	-7 (-16 to 2)	0.14
Vitamin B ₁₂ (pmol/L)	304 (126)	467 (381)	163 (48 to 278)	0.007
Vitamin B ₁₂ < 150 pmol/L	1/39 (2.6 %)	4/38 (10 %)		0.38
Vitamin D (nmol/L)	48 (20)	48 (19)	0 (-7 to 6)	0.92
Vitamin D < 50 nmol/L	23/38 (59 %)	22/37 (56 %)		1.0
Calcium, albumin-corrected (mmol/L)	2.39 (0.07)	2.41 (0.05)	0.013 (-0.009 to 0.035)	0.24
Parathyroid hormone (PTH) (pmol/L)	5.2 (1.8)	4.7 (1.2)	-0.3 (-0.8 to 0.2)	0.21
Secondary hyperparathyroidism	3/39 (8 %)	2/38 (5 %)		1.0
Bone health				
Bone mineral content, BMC (g)	2 642 (283)	2 590 (361)	-92 (-134 to -50)	< 0.001
Bone mineral density, BMD z-score	1.19 (1.08)	0.67 (1.07)	-0.51 (-0.66 to -0.36)	< 0.001
Hypoglycaemia				
Glucose after oral glucose tolerance test < 2.8 mmol/L	0/37 (0 %)	20/33 (61 %)		NA

¹All baseline and one-year values are based on data from at least 37 of 39 (95 %) patients (with the exception of serum glucose after an oral glucose tolerance test at one-year follow-up).

Discussion

The results from the non-randomised 4XL study show significantly greater one-year weight loss and improvement in cardiometabolic risk factors after gastric bypass combined with lifestyle intervention than after lifestyle intervention alone. However, the non-randomised study design, the relatively small number of patients who underwent surgery, and the short follow-up time preclude us from evaluating whether the benefits of weight loss outweigh the risk of long-term complications. Nor can we exclude the possibility that systematic differences between the treatment groups in both selection and dropout may have affected the outcomes, reducing the internal validity and generalisability.

As of 9 October 2020, only a single randomised controlled study had been published comparing the effects of lifestyle intervention to those of bariatric surgery in adolescents, and even this study featured a type of surgery (gastric banding) that is rarely used (14). The effects on BMI of laparoscopic Roux-en-Y gastric bypass surgery versus caloric restriction (low calorie diet) are being compared in an ongoing randomised controlled trial of 13–16-year-olds with BMI > 35 kg/m². The results from this study may strengthen the existing evidence base (<https://clinicaltrials.gov/ct2/show/NCT02378259>).

Our results are consistent with findings from two non-randomised studies that showed approximately 30 % weight loss one and two years after gastric bypass surgery, respectively (15, 16). The Swedish AMOS study compared gastric bypass surgery with conventional treatment and showed 31–32 % weight loss in the surgery group versus 3 % weight gain in the control group (16). A US study showed approximately 30 % weight loss one and two years after bypass surgery (15). The significant improvement in cardiometabolic risk factors in the surgery group confirms findings from previous observational studies (16, 17).

Two (5 %) postoperative complications were recorded, which is in accordance with international experience (16, 18). The risk of long-term complications following bariatric surgery in adolescents is poorly documented (9) and has not been examined in the current analysis either.

Anaemia and vitamin and mineral deficiencies are known adverse effects after gastric bypass (7, 16). In the current study, mean levels of haemoglobin, ferritin, calcium, vitamin D and vitamin B₁₂ had not fallen significantly after one year. However, at the one-year follow-up, a number of patients had anaemia, iron deficiency or low vitamin B₁₂ levels (Table 4), and about 2 out of 3 patients (61 %) had two-hour hypoglycaemia after an oral glucose tolerance test (blood sugar < 2.8 mmol/L). The incidence of two-hour hypoglycaemia was higher than shown previously in adults (19, 20), and lower age is known to be a risk factor (21). No fractures were recorded, and bone mineral measurements did not show a decrease in (mean) bone density to below that expected for age. It is nevertheless concerning that gastric bypass surgery is associated with an increased fracture risk (22) and postprandial hypoglycaemia. Lifelong follow-up with diagnostic testing and use of preventive measures would seem to be necessary.

The 4XL study is ongoing, and a ten-year follow-up is planned. A particular strength of the study is that the intervention group is being compared with an actively treated control group, with both groups of participants fulfilling the same inclusion criteria. In addition, the study is being run by a centre with specialist expertise in family-based lifestyle interventions in adolescents, bariatric surgery and clinical research. The complexity of the assessment and follow-up of this patient group requires a seamless and close collaboration between healthcare professionals specialising in the treatment of childhood obesity and surgeons with expertise in bariatric surgery.

Weaknesses of the study include the relatively small number of patients in the surgery group, the long recruitment period and differences between the groups in baseline age (17

years vs. 16 years) and BMI (45.6 kg/m² vs. 43.3 kg/m²). The latter, however, had little effect on the between-group difference in the change in the primary outcome measure, which was adjusted for baseline weight in the primary analyses, and further adjustment for age did not affect the results. Although the sample size was lower than planned (n = 50 in the surgery group), the dropout rate (5 %) was lower than expected (30 %). The study therefore had sufficient power to answer the primary research question on weight loss as soon as 39 patients had attended the one-year follow-up.

A recently published meta-analysis showed that health-related quality of life improved significantly after surgery in adolescents, especially in the first few years, but that few data are available on the long-term incidence of psychosocial and mental health problems (23). Long-term results from the AMOS study show that mental health problems do not necessarily decrease after gastric bypass surgery in adolescents, and that individuals who undergo surgery may have a greater need for psychiatric help than those who do not undergo surgery (24). Health-related quality of life, psychological status, eating behaviour and long-term complications are all topics for future analyses and publications from the 4XL study.

Our results confirm that laparoscopic Roux-en-Y gastric bypass can be performed with satisfactory weight loss, improvement of cardiometabolic risk factors and a low incidence of early postoperative complications. The study also indicates that the incidence of adverse effects and complications is similar in the short-term to that observed in adults (7), but the study is too small at present to be able to draw definite conclusions about the incidence and severity of complications. Little is known about the long-term effects and complications of weight loss surgery in adolescents (9). It is therefore difficult to know whether bariatric surgery should be offered to more young people with morbid obesity, or whether it is better to recommend waiting until adulthood. Arguments *for* obesity surgery in adolescence are the possibility of significant weight loss, improved quality of life and a reduced risk of future obesity-related disease. Arguments *against* are the risk of serious complications, anaemia, hypoglycaemia, vitamin and mineral deficiencies, and mental health problems.

MAIN FINDINGS

Adolescents who underwent laparoscopic gastric bypass surgery combined with lifestyle intervention had significantly greater one-year weight loss (31 %) than adolescents who received lifestyle intervention alone.

Surgery was associated with significant improvement in cardiometabolic risk factors, whereas lifestyle intervention was not.

A relatively high proportion of patients who underwent surgery had anaemia (10 %), iron deficiency (21 %) and low vitamin B₁₂ levels (10 %) after one year.

Twenty out of 33 patients (61 %) had low blood glucose two hours after oral glucose tolerance testing.

REFERENCES:

1. Must A, Strauss RS. Risks and consequences of childhood and adolescent obesity. *Int J Obes Relat Metab Disord* 1999; 23 (Suppl 2): S2–11. [PubMed][CrossRef]
2. Llewellyn A, Simmonds M, Owen CG et al. Childhood obesity as a predictor of morbidity in adulthood: a systematic review and meta-analysis. *Obes Rev* 2016; 17: 56–67. [PubMed][CrossRef]
3. Steinbeck KS, Lister NB, Gow ML et al. Treatment of adolescent obesity. *Nat Rev Endocrinol* 2018; 14: 331–44. [PubMed][CrossRef]
4. Skodvin VA, Lekhal S, Kommedal KG et al. Livsstilsbehandling av barn og ungdom med alvorlig

fedme – resultater etter ett år. Tidsskr Nor Legeforen 2020; 11: 901–7.

5. Al-Khudairy L, Loveman E, Colquitt JL et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years. *Cochrane Database Syst Rev* 2017; 6: CD012691. [PubMed][CrossRef]
6. Hofsø D, Fatima F, Borgeraas H et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. *Lancet Diabetes Endocrinol* 2019; 7: 912–24. [PubMed][CrossRef]
7. Jakobsen GS, Småstuen MC, Sandbu R et al. Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities. *JAMA* 2018; 319: 291–301. [PubMed][CrossRef]
8. Treadwell JR, Sun F, Schoelles K. Systematic review and meta-analysis of bariatric surgery for pediatric obesity. *Ann Surg* 2008; 248: 763–76. [PubMed][CrossRef]
9. Ruiz-Cota P, Bacardí-Gascón M, Jiménez-Cruz A. Long-term outcomes of metabolic and bariatric surgery in adolescents with severe obesity with a follow-up of at least 5 years: A systematic review. *Surg Obes Relat Dis* 2019; 15: 133–44. [PubMed][CrossRef]
10. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents National Heart, Lung, and Blood Institute. . Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics* 2011; 128 (suppl 5): S213–56. [CrossRef]
11. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. *Diabetes Care* 2020; 43 (Suppl 1): S14–31. [PubMed][CrossRef]
12. Dong Y, Song Y, Zou Z et al. Updates to pediatric hypertension guidelines: influence on classification of high blood pressure in children and adolescents. *J Hypertens* 2019; 37: 297–306. [PubMed][CrossRef]
13. Johansen MJ, Gade J, Stender S et al. The Effect of Overweight and Obesity on Liver Biochemical Markers in Children and Adolescents. *J Clin Endocrinol Metab* 2020; 105: dgz010. [PubMed][CrossRef]
14. O'Brien PE, Sawyer SM, Laurie C et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. *JAMA* 2010; 303: 519–26. [PubMed][CrossRef]
15. Inge TH, Courcoulas AP, Jenkins TM et al. Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents. *N Engl J Med* 2016; 374: 113–23. [PubMed][CrossRef]
16. Olbers T, Gronowitz E, Werling M et al. Two-year outcome of laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity: results from a Swedish Nationwide Study (AMOS). *Int J Obes* 2012; 36: 1388–95. [PubMed][CrossRef]
17. Black JA, White B, Viner RM et al. Bariatric surgery for obese children and adolescents: a systematic review and meta-analysis. *Obes Rev* 2013; 14: 634–44. [PubMed][CrossRef]
18. Arafat M, Norain A, Burjonrappa S. Characterizing Bariatric Surgery Utilization and Complication Rates in the Adolescent Population. *J Pediatr Surg* 2019; 54: 288–92. [PubMed][CrossRef]
19. Hofsø D, Nordstrand N, Johnson LK et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. *Eur J Endocrinol* 2010; 163: 735–45. [PubMed][CrossRef]
20. Pigeyre M, Vaurs C, Raverdy V et al. Increased risk of OGTT-induced hypoglycemia after gastric bypass in severely obese patients with normal glucose tolerance. *Surg Obes Relat Dis* 2015; 11: 573–7. [PubMed][CrossRef]
21. Hofsø D, Birkeland KI, Holst JJ et al. Gastric bypass surgery has a weight-loss independent effect on post-challenge serum glucose levels. *Diabetol Metab Syndr* 2015; 7: 69. [PubMed][CrossRef]
22. Paccou J, Martignène N, Lespessailles E et al. Gastric Bypass But Not Sleeve Gastrectomy Increases Risk of Major Osteoporotic Fracture: French Population-Based Cohort Study. *J Bone Miner Res* 2020; 35: 1415–23. [PubMed][CrossRef]
23. Trooboff SW, Stucke RS, Riblet NB et al. Psychosocial Outcomes Following Adolescent Metabolic and Bariatric Surgery: a Systematic Review and Meta-Analysis. *Obes Surg* 2019; 29: 3653–64. [PubMed][CrossRef]

24. Järholm K, Bruze G, Peltonen M et al. 5-year mental health and eating pattern outcomes following bariatric surgery in adolescents: a prospective cohort study. *Lancet Child Adolesc Health* 2020; 4: 210–9. [PubMed][CrossRef]

Published: 9 November 2020. Tidsskr Nor Lægeforen. DOI: 10.4045/tidsskr.20.0526

Received 11.6.2020, first revision submitted 4.10.2020, accepted 9.10.2020.

© The Journal of the Norwegian Medical Association 2020. Downloaded from tidsskriftet.no